Novo Nordisk has announced a significant price reduction for its diabetes medication, Ozempic, bringing the cost down to $499 per month for eligible cash-paying U.S. customers. This move aims to increase accessibility for patients, especially those without insurance coverage for the medication. The company has teamed up with GoodRx, which is set to expand access to not only Ozempic but also other GLP-1 drugs like Wegovy. The announcement has led to a surge in stock prices for GoodRx as they collaborate to provide more affordable options at pharmacies across the country.